Recombinant CD44 , CD44V (Bivatuzumab Biosimilar) antibody
Quick Overview for Recombinant CD44 , CD44V (Bivatuzumab Biosimilar) antibody (ABIN7597560)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Research Grade Bivatuzumab Biosimilar Antibody
-
Specificity
- Hyaluronate receptor, MDU2, HUTCH-I, MDU3, Phagocytic glycoprotein I, CDw44, Epican, Phagocytic glycoprotein 1, ECMR-III, CD44, Hermes antigen, PGP-1, PGP-I, GP90 lymphocyte homing/adhesion receptor, LHR, CD44 antigen, MIC4, Extracellular matrix receptor III, Heparan sulfate proteoglycan
-
Purification
- Protein A or G purified from cell culture supernatant.
-
Purity
- >95 % by SDS-PAGE.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 0.01M PBS, pH 7.4.
-
Storage
- 4 °C,-20 °C,-80 °C
-
Storage Comment
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
-
Expiry Date
- 12 months
-
-
- CD44 , CD44V (Bivatuzumab Biosimilar)
-
Alternative Name
- Bivatuzumab Biosimilar
-
Target Type
- Biosimilar
-
Background
- Hyaluronate receptor, MDU2, HUTCH-I, MDU3, Phagocytic glycoprotein I, CDw44, Epican, Phagocytic glycoprotein 1, ECMR-III, CD44, Hermes antigen, PGP-1, PGP-I, GP90 lymphocyte homing/adhesion receptor, LHR, CD44 antigen, MIC4, Extracellular matrix receptor III, Heparan sulfate proteoglycan
-
UniProt
- P16070
-
CAS-No
- 214559-60-1
Target
-